Corcept Therapeutics

Avidity Biosciences

Krystal Biotech

Arcellx

Alkermes

Crinetics Pharmaceuticals Inc

Immunovant Inc

Denali Therapeutics

Merus

Xenon Pharmaceuticals

ALPS Medical Breakthroughs ETF

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

SPDR S&P 500 ETF Trust

If there were a defining sector for investors this year, it has been tech investing. The ascendance of AI has lifted valuations and investor portfolios, boosting the market as a whole.

Biotech ETF SBIO Laps Tech Rivals Over 1 Year

LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symbol: SBIO), with offices in Dubai and provider of AI models for data generated in the new space industry economy, have signed a Letter of Intent (LOI) to partner on joint satellite payload design and development of CubeSats along with measuring radiation and launching payloads for biotechnology, pharmaceutical compani.

Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry

The effects of the Federal Reserve's recent interest rate cut haven't fully been felt by the economy or financial markets. But the first instance of U.S. monetary easing in over four years may be a boon for capital-intensive biotech companies.

Tailwinds Emerging for This Biotech ETF

In a somewhat quiet fashion, long-lagging biotech stocks and exchange traded funds are perking up. The ALPS Medical Breakthroughs ETF (SBIO) is part of that group.

Biotech Stocks Are Perking Up. This ETF Is Responding

Alerian MLP ETF

Amplify Online Retail ETF

American Century U.S. Quality Growth ETF

ROBO Global Robotics and Automation ETF

VictoryShares Free Cash Flow ETF

The TMX VettaFi business segment is less than a year old, but it is already getting recognized for the breadth of its capabilities. Last week, we were named a finalist by ETF Express in four award categories.

VettaFi Is Finalist for 4 ETF Awards

While many investors are on the lookout for ETF opportunities in rate cuts, one particular strategy is already standing out. The biotech ETF SBIO is riding some positive momentum thanks to some major changes in the space this year.

Biotech ETF SBIO Rides Strong Momentum into Rate Cuts

Following some notable uncertainty in recent years, M&A activity looks to be in recovery. In the first half of this year, biotech M&A activity saw some positive numbers, per a new J.P.

Positive Biotech M&A Activity in 1H Boosts Case for Biotech ETF SBIO

Avantis US Small Cap Equity ETF

WisdomTree U.S. SmallCap Earnings Fund

JPMorgan Active Small Cap Value ETF

Invesco KBW Regional Banking ETF

iShares US Small Cap Value Factor ETF

The US economy expanded at a faster-than-expected pace in the second quarter of 2024. Small-cap stocks generally lead the way higher on improving American economy.

Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?

On the lookout for an ETF that might respond particularly well to rate cuts? One rate-sensitive ETF to watch is seeing returns spike even before rate cuts arrive.

Returns Spiking for This Rate-Sensitive ETF

Invesco Nasdaq Future Gen 200 ETF

KBWR, QQQS, SVAL, EES and SBIO are included in this Analyst Blog.

The Zacks Analyst Blog KBWR, QQQS, SVAL, EES and SBIO

Small-cap stocks have staged a strong comeback buoyed by the Trump trade resurgence and the growing expectations of the Fed cutting rates in September.

5 Small-Cap ETFs at the Forefront of the Latest Rally

There's long been talk of a new wave of biotech mergers and acquisitions activity coming to life. In modest amounts, there has been evidence of that playing out.

Patent Cliffs Could Spark Wave of Biotech M&A

In the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which well-heeled blue-chip pharmaceutical companies would spend some of their cash on faster-growing biotech firms.

Big Pharma Has the Firepower for Biotech Deal-Making

Many investors hoping for a resurgence by biotech stocks have hitched their wagons to the Federal Reserve lowering interest rates. That's a practical bet because biotech is a rate-sensitive industry.

Biopharma R&D Trends Could Bode Well for This ETF

Biotech stocks and exchange traded funds have endured a lengthy rough patch. And the pain has been particularly acute for small- and mid-cap fare.

There Could Be Signs of Life for Biotech ETFs

First Trust US Equity Opportunities ETF

Renaissance IPO ETF

IQ Merger Arbitrage ETF

With lower interest rates now in sight and renewed confidence in the stock market, deal making activity should pick up in 2024 after a slow couple of years. For retail investors, this could lead to new opportunities to invest in emerging industries and the potential to capture early returns.

How ETF Investors Can Take Advantage of Deal Activity

Principal U.S. Small-Cap Multi-Factor Index ETF

AlphaMark Actively Managed Small Cap ETF

Motley Fool Small-Cap Growth ETF

Invesco S&P SmallCap Momentum ETF

Wall Street's newfound bullishness on small caps reflects a notable shift in market dynamics, with several analysts predicting continued growth.

Inside Small-Cap's 3-Year Best Surge in Popularity: ETFs in Focus

GraniteShares HIPS US High Income ETF

ALPS Sector Dividend Dogs ETF

Many of us were prepping for year-end (or on vacation in Belize, in my case) in December. However, index providers were hard at work to ensure certain ETFs fully reflected the investment criteria advisors have come to expect.

What's Now Inside Some Fundamentally Focused ETFs

Proshares S&P Kensho Cleantech ETF

VanEck Office and Commercial REIT ETF

SPDR S&P Regional Banking ETF

Valkyrie Bitcoin Miners ETF

Wall Street sizzled in December, with all three major indices touching a series of new highs.

5 Market-Beating Sector ETFs of December

With the year drawing to a closer, investors may be on the lookout for a strategy or idea that has some momentum. In a notable turnaround from earlier this year, biotech looks to be one such area to consider.

Biotech ETF SBIO's Momentum Strong to End 2023

Global X Artificial Intelligence & Technology ETF

Amplify Lithium & Battery Technology ETF

Global X Cybersecurity ETF

Bitwise Web3 ETF

Roundhill Generative AI & Technology ETF

First Trust NASDAQ Cybersecurity ETF

Loncar Cancer Immunotherapy ETF

VanEck Video Gaming and eSports ETF

Amplify Cybersecurity ETF

iShares Genomics Immunology and Healthcare ETF

iShares Cybersecurity and Tech ETF

Global X Lithium & Battery Tech ETF

TrueShares Technology, AI and Deep Learning ETF

Roundhill Ball Metaverse ETF

MUSQ Global Music Industry ETF

Defiance Quantum ETF

Robo Global Artificial Intelligence ETF

SoFi Web 3 ETF

WisdomTree Cybersecurity Fund

Wisdomtree Artificial Intelligence And Innovation Fund

To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.

Disruptive Tech Theme of the Week: 7 Disruptive Themes for 2024

It's been a complicated year for tech firms outside those “Magnificent Seven” names that have, to some degree, outgrown a simple “tech” distinction. High interest rates have taken a toll on tech firms.

Biotech ETF SBIO Sees Buy Signal Amid Hot Returns

Tech has been a big driver of market resilience this year, with AI specifically boosting earnings for all kinds of companies. That said, technology isn't just moving forward in software.

Play US Gene Treatment Approval in SBIO

Biotechnology is certainly on the list, if not at the top, of high-growth industries in dire need of a rebound. Following enthusiasm for COVID-19 vaccines in late 2020 and part of 2021, biotechnology stocks and ETFs have disappointed investors.

Innovation Could Propel Biotechnology Bounce

ARK Genomic Revolution Multi-Sector ETF

iShares MSCI Israel ETF

VanEck Vectors Israel ETF

Subversive Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Invesco WilderHill Clean Energy ETF

Invesco Solar ETF

Strategic Crispr & Gene Editing Technology ETF

After a downbeat September, October too remained volatile for Wall Street due to higher rates.

News for ALPS Medical Breakthroughs ETF ETF (SBIO)